Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 24 Sept 2025, 04:48 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The video discusses HIMS stock, revisiting a previous buy recommendation from August 5th, 2025. The stock has risen almost 30% in the past month, warranting a reevaluation. The analysis focuses on the company's revenue growth, which has increased from $100 million to $2 billion between 2020 and 2025, resulting in a 79% compound annual growth rate. Even without the weight loss treatments, revenue and customer growth are reportedly strong. The company's operating profit margin is 6.5% in the trailing 12-month period, up from -39% in 2021. The largest expense for HIMS is sales and marketing, which benefits from economies of scale as the company grows. While there are claims that HIMS is selling copycat versions of the weight loss treatments, the management reports growing.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
